Volitionrx Limited · AMEX:VNRX
Volitionrx — Investor Presentation (March 2023)
32 slides from Volitionrx's investor presentation, March 2023
Slide 1: Corporate Deck
Corporate Deck March 2023 Property Propertyof Volition©©2023 ofVolition 2023 Slide 1
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncer
Slide 3: Who We Are
Who We Are • Diagnostic company focusing on epigenetic markers • Epigenetics = on top of, or in addition to [the genome] • Human and Veterinary use cases: • Screening • Monitoring (disease progression and response to treatment) • We believe our addressable markets are significant $ 70 billion TAM1.
Slide 4: What sets us apart?
What sets us apart? 122 patents Key Differentiators: pending worldwide1. 34 patent • our Intellectual Property families (plus 3 in-licensed) 1. 70 additional • Our patent portfolio is growing¹ patents granted worldwide in • Our products are protected until at least growing IP portfolio1. 2031 includ
Slide 5: What sets us apart? Powered By
What sets us apart? Powered By Property of Volition© 2023 Slide 5
Slide 6: How does the Nu.Q Test work?
How does the Nu.Q® Test work? Nucleosomes are small fragments of chromosome composed of a segment of DNA wrapped. Cancer and cell death release nucleosomes into the blood. Nucleosomes can be measured using antibodies. Measuring nucleosome levels can be diagnostic markers for disease. The Nu.Q® Test
Slide 7: Product Pillars
Product Pillars Powered by powered by Nu.Q® Property of Volition© 2023 Slide 7
Slide 8: Commercial Strategy
Commercial Strategy Overall strategy • R&D conducted by Volition and its research partners • Distribution via global players and in fragmented markets, regional companies Partner with established diagnostic companies to market, sell, and process our test • Leveraging their networks and expertise • M
Slide 9: Key Focus Areas
KEY Focus Areas Property of Volition© 2023 Slide 9
Slide 10: Sepsis & Thrombosis
Sepsis & Thrombosis Property of Volition© 2023 Slide 10
Slide 11: Developing a diagnostic solution for NETosis
Developing a diagnostic solution for NETosis An abnormal immune response Property of Volition© 2023 Slide 11
Slide 12: NETosis Opportunity
NETosis Opportunity • NETosis NETosis = unique form of cell death characterized by the release of decondensed chromatin within the context of the innate immune response to an infection • Very large number of use cases: • Initial focus on sepsis, coagulation/ thrombosis and transplantation • Risk str
Slide 13: NETosis Opportunity: Update
NETosis Opportunity : Update CE Mark • May 2022 Granted • DXOCRO FDA study now underway • First phase of study focused on sepsis completed • An application to the FDA’s Breakthrough Device Program is expected to be submitted in the first half of 2023 • Clinical study signed in collaboration with MDA
Slide 14: NETosis Opportunity: Commercial Update
NETosis Opportunity : Commercial Update • Two Centers of Excellence operational, two deep in legal discussions and further centers identified for ramp up in EU and U.S. in 2023 • Licensing & Supply discussions underway with major companies of the coagulation market Property of Volition© 2023 Slide 1
Slide 15: Nu.Q Vet Cancer Test
Nu.Q® Vet Cancer Test Property of Volition Veterinary Diagnostics Development© 2023 Slide 15
Slide 16: Number of pet dogs in the U.S.
Number of pet dogs in the U.S.1 Pets improve our health2 Approximately 76% of pet 84 million owners report improved health 69 million3 91% of pet owners2 Say they would be more likely to maintain U.S. households have a pet dog their pet’s health, including regular check- ups with their veterinarian
Slide 17: Nearly 50% Early Detection
Human/Canine Cancer1. Dogs Diagnosed with Cancer Annually2. 25-40% of all Approximately humans and dogs 6 million develop cancer Nearly 50% Early Detection Of dogs over the age of 10 will Can lead to improved treatment outcomes develop cancer3. 1.Sarver, A., Makielski, K., DePauw, T., Schulte, A., &
Slide 18: Veterinary Opportunity
Veterinary Opportunity • Significant market opportunity TAM $ 11 billion1. • Global canine and feline populations for screening and monitoring • Nu.Q® Vet opportunity > $1.5 Billion TAM $11B+ # Tests on Volition’s platform 200M+ Volition’s opportunity $1.5B+ *Retail Pricing Addressable Market $50 Gl
Slide 19: Our Current Product Proposition
Our Current Product Proposition • The Nu.Q® Vet Cancer Test is positioned for use in the annual health check of older dogs (those that are seven years and older) and may also be a complementary test for younger dogs at high risk for developing cancer in their lifetimes, such as Golden Retrievers • I
Slide 20: Product Launch Roadmap
Product Launch Roadmap Launched Expected Launches • IDEXX Reference Laboratories • Heska Point of Care Test, worldwide H1 23 • Heska Veterinary Diagnostics Lab (Pre-Orders now being taken in the U.S.) (U.S.) • Monitoring claim Q2 23 • Texas A&M GI Lab • SAGE Healthcare • SCIL Lab Europe • DNATech, P
Slide 21: Longer Term Nu.Q Vet
Longer Term Nu.Q® Vet Property of Volition Veterinary Diagnostics Development© 2023 Slide 21
Slide 22: Longer Term Products in Development
Longer Term Products in Development NETosis Elite Production Cancer in Equestrian Animals Cats *NEW* Study underway in EU Property of Volition Veterinary Diagnostics Development© 2023 Slide 22
Slide 23: Commercial Strategy & Market Opportunity
Commercial Strategy & Market Opportunity Property of Volition Veterinary Diagnostics Development© 2023 Slide 23
Slide 24: Commercial Deals in Place (Jan. 2023)
Commercial Deals in Place (Jan. 2023) 1. Signed a global supply agreement with a IDEXX Laboratories Inc. to provide test through worldwide reference lab network • Worldwide customer reach through its global reference laboratory network • Launched in the U.S. in Jan 2023. Other countries expected to
Slide 25: Nu.Q Vet Cancer Test Opportunity Simulation
Nu.Q® Vet Cancer Test Opportunity Simulation1. 240 $225m 220 200 180 Revenue 160 $150m Opportunity 140 ($mn) 120 100 80 $75m 60 40 $38m ~ Total Burn Rate $26m $15m $24m in 2021 20 0 2m 3.5m 5m 10m 20m 30m *Not revenue guidance and not indicative of the Reference Lab to Number of POC market split & m
Slide 26: Summary & Financial Update
Summary & Financial Update Property Propertyof Volition©©2023 ofVolition 2023 Slide 26
Slide 27: Summary
Summary • Diagnostic company focusing on epigenetic markers • Human and Veterinary use cases for screening & monitoring life altering diseases • We believe our addressable markets are significant - $70 billion TAM • Two key product areas anticipated in the short term (2023-2024) and a number of pote
Slide 28: Key Financials Full Year 2022
Key Financials Full Year 2022 NYSE American: VNRX Market Cap: $114.5m* 52-week range: $1.31-$3.30* Cash used in operating activities:12-month average Approx. $1.3/mth** Cash-on-hand: ~$10.9m** * As of Mar 1, 2023 **As of December 31, 2022 Property Propertyof Volition©©2023 ofVolition 2023 Slide 28
Slide 29: Questions?
Questions? Thank you for your interest in Volition. For more details, please visit www.volition.com Property Propertyof Volition©©2023 ofVolition 2023 Slide 29
Slide 30: The Team
The Team Property Propertyof Volition©©2023 ofVolition 2023 Slide 30
Slide 31: Executive Team
Executive Team Dill Faulkes PhD, Executive Chairman - Dill Faulkes has over 30 years of entrepreneurial and managerial experience as the founder and CEO of several software companies within the United Kingdom and the United States. As the Founder and one of the Benefactors of the Dill Faulkes Educat
Slide 32: Executive Team
Executive Team Jake Micallef PhD MBA, Chief Scientific Officer - Jake is an experienced scientist with expertise in research and development and in the management of biotechnical companies, including manufacturing and establishing operations. He received his BSc and a PhD in Physical Chemistry from